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Abstract
Protease inhibitors play a decisive role in maintaining homeostasis and eliciting antimicrobial activities. Invertebrates like
the horseshoe crab have developed unique modalities with serine protease inhibitors to detect and respond to microbial
and host proteases. Two isoforms of an immunomodulatory two-domain Kazal-like serine protease inhibitor, CrSPI-1 and
CrSPI-2, have been recently identified in the hepatopancreas of the horseshoe crab, Carcinoscorpius rotundicauda. Full
length and domain 2 of CrSPI-1 display powerful inhibitory activities against subtilisin. However, the structure and function
of CrSPI-1 domain-1 (D1) remain unknown. Here, we report the crystal structure of CrSPI-1-D1 refined up to 2.0 A ˚ resolution.
Despite the close structural homology of CrSPI-1-D1 to rhodniin-D1 (a known thrombin inhibitor), the CrSPI-1-D1 does not
inhibit thrombin. This prompted us to modify the selectivity of CrSPI-1-D1 specifically towards thrombin. We illustrate the
use of structural information of CrSPI-1-D1 to modify this domain into a potent thrombin inhibitor with IC50 of 26.3 nM. In
addition, these studies demonstrate that, besides the rigid conformation of the reactive site loop of the inhibitor, the
sequence is the most important determinant of the specificity of the inhibitor. This study will lead to the significant
application to modify a multi-domain inhibitor protein to target several proteases.
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Introduction
The innate immune system is the first line of inducible host
defense against various pathogens and their products [1]. Secreted
proteases serve important roles in pathogen virulence. Several
families of protease inhibitors from the host play an important role
in innate immunity by inactivating and clearing the proteases from
the pathogens. Horseshoe crab hemocytes contain granules filled
with several serine protease zymogens. During mechanical injury or
pathogen invasion, the granules are released into the extracellular
milieu by exocytosis, and precursor forms of clotting enzymes are
activated by a serine protease cascade triggered by bacterial
endotoxin. This pathogen-induced cascade is regulated by three
serpins, also known as Limulus intracellular coagulation inhibitors
(LICI-1, LICI-2 and LICI-3) [2,3,4,5]. Protease inhibitors, thus
plays multiple roles by maintaining homeostasis and eliciting innate
immunity [6]. This defense system is essential for the survival and
perpetuation of all multicellular organisms [6,7].
The Kazal family is one amongst 18 families of serine protease
inhibitors, and is mainly divided into two groups: the classical and
the non-classical inhibitors. Non-classical Kazal inhibitors [8]
consist of one to seven repeated domains, with each domain
constituting 50–60 amino acid residues. Regardless of whether a
domain is functionally active, it contains a reactive site loop (RSL)
exposed at the surface. The serine protease inhibitor functions as a
substrate analogue, but the resulting enzyme-inhibitor complex is
very stable [9].
We recently reported a two-domain non-classical Kazal serine
protease inhibitor from the hepatopancreas of Carcinoscorpious
rotundicauda (CrSPI) with a possible dual function of inactivating
pathogen protease (subtilisin) and host protease (furins). The full
length and domain 2 of CrSPI-1 have been shown to contain full
inhibitory activities against subtilisin. However, the function of the
domain 1 of CrSPI (hereafter referred to as CrSPI-1-D1) is not yet
characterized [10]. Analysis of the CrSPI-1-D1 sequence shows
that it is significantly homologous to that of rhodniin-D1 from
Rhodnius prolixus, which is a thrombin inhibitor [11]. A number of
endogenous thrombin inhibitors are available, and the most potent
one is hirudin from the medicinal leech, Hirudo medicinalis [12].
In spiteofseveralstudies on serineproteaseinhibitors,CrSPIsare
relatively new and potent [10]. There are several unexplored
potentials and unanswered questions about CrSPIs, for example,
what is the structural homology of the CrSPI domains, among
themselves and other SPIs? What is the variance of target specificity
and inhibition? In order to address these questions we have
undertaken the structural and functional studies on CrSPI-1-D1.
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2.0 A ˚ resolution. Despite the close structural homology of CrSPI-1-
D1 to rhodniin-D1, the native CrSPI-1-D1 does not inhibit
thrombin. This motivated us to modify the selectivity of the
CrSPI-1-D1 to specifically target thrombin. We show that
sequential mutations in the RSL region of CrSPI-1-D1 generated
a potent and specific thrombin inhibitor. The full length CrSPI-1
with this modified role of CrSPI-1-D1 as a thrombin modulator,
might play a central role in regulating not only hemostasis but also
inflammation, and may provide a close link between these processes
and how they might co-evolve in the biological system. Further-
more, the possibilities to further develop this D1 mutant into a
shorter yet active anti-thrombin holds potentials for biomedical
applications as a coagulation modulator [13,14,15,16,17,18,19,20].
Results
Overall structure
The structure of CrSPI-1-D1 was solved by molecular
replacement method and refined to a final R-factor of 0.21
(Rfree=0.25) at 2.0 A ˚ resolution. The model has been refined with
good stereo chemical parameters (Table 1). There are two CrSPI-
1-D1 monomers in the asymmetric unit. The structure of CrSPI-1-
D1 mostly consists of loops with a two-strand (Val8-Gly10 and
Gly13-Tyr16) b-sheet and a two-turn a-helix (Figure 1). In
addition, a single turn a-helix (Trp33-Cys36) is present at the C-
terminal. A disulphide bond is located between Cys1 and Cys20 to
help maintain the rigidity of the RSL. The carboxyl terminus is
linked to the N-terminal through a second disulphide bridge,
Cys9-Cys36 (Figure 1A).
Structural comparison
A search for topologically similar domains within the PDB
database using the DALI program [21] revealed that the structural
features of CrSPI-1-D1 resemble the typical non-classical Kazal
type inhibitor [8]. The highest structural similarity is observed
between hirudin, the leech-derived tryptase inhibitor from H.
medicinalis and CrSPI-1-D1, yielding an rmsd of 1.9 A ˚ for 36 Ca
atoms (pdb code 1ldt). This is followed by a thrombin protease
inhibitor, rhodniin domain 1 (rhodniin-D1) from Rhodnius prolixus,
which yielded an rmsd of 2.0 A ˚ for 36 Ca atoms (pdb code 1tbq). In
addition to the structural homology, the CrSPI-1-D1 and rhodniin-
D1 display 42%sequence identity while only 35% sequence identity
wasobserved with hirudin.Thestructure-basedsequencealignment
revealed that most of the structurally invariant residues are located
at the carboxy terminus, including the RSL, b1, b2a n da1o f
CrSPI-1-D1(Figure 2).Theseobservedfeaturesprovidedaclue that
CrSPI-1-D1 might specifically target thrombin after modifications
of a few residues in the RSL, and this prompted us to change the
specificity of CrSPI-1-D1 to target thrombin.
The reactive-site loop
Although the sequence of the reactive-site loop (RSL) is different
in several families of serine protease inhibitors, the conformation of
the RSL is similar [10,11]. Like other Kazal-type inhibitors, the
disulfide bonds formed by cysteine residues at the P3 and P59
positions (Cys1 and Cys9 in CrSPI-1-D1) hold the RSL in a
relatively rigid conformation. Besides, there are several internal
hydrogen bonds (,3.2 A ˚) which help maintain the rigidity of the
RSL in the CrSPI-1-D1. Figure 3c shows selected hydrogen
bonding contacts between RSL and CrSPI-1-D1. Notably, strong
intra-molecular H-bonds (,3.0 A ˚) were observed between the
carbonyl oxygen of Pro2 (P2 position) and amide nitrogen of Thr4
(P19 position); Asn18 and Phe21, ND2 of Asn18 interacts with the
main chain carbonyl atoms of Pro2 and Thr4 at the P2 and P19
positions of the RSL, respectively (Table S1). Similar interactions
were observed in rhodniin-D1 and other protease inhibitors such as
the turkey ovomucoid third domain, OMTKY3, although there are
different amino acids in those positions [22]. In addition to the S-S
bonds, these hydrogen bonds are essential to maintain the rigidity of
the RSL during the inhibition of the cognate enzyme. Although a
similar rigid conformation is found in these inhibitors, they
recognize the substrates differently. This clearly shows that in
addition to the rigid conformation, the sequence of the RSL dictates
the selectivity towards a particular protease. Thus, we have mutated
the RSL side chains of CrSPI-1-D1 to specifically target thrombin.
Mutations to change the specificity
Following the structure determination of CrSPI-1-D1, the next
main objective was to elucidate the inhibitory efficiency of this
domain. Our previous studies showed that full length as well as
domain 2 of CrSPI-1 is a specific inhibitor of subtilisin, however
the specificity of domain-1 is not yet established [10]. An analysis
of P3 to P49 residues of the RSLs of various substrates like binding
serine protease inhibitors such as for subtilisin, thrombin, trypsin,
chymotrypsin and furin was performed to identify the minimum
Table 1. Data collection and refinement statistics of CrSPI-1-
D1.
Experiment
Cell parameters (A ˚, u) a=25.5, b=37.2, c=36.5,
a=90, b=99.8,c=90
Space group P21
Data collection
a
Resolution range (A ˚) 50.0-2.0 (2.07-2.00)
Observed Reflections 28,930
Unique Reflections 4,535
Redundancy 6.4 (3.2)
Completeness (%) 97.3 (80.7)
Overall (I/sI) 31.3
Rsym
b 0.046 (0.061)
Refinement
Resolution range (A ˚) 20.0-2.0
Number of Reflections used 4432
R factor
c/Rfree
d (%) 21.47/25.56
RMSD bond lengths (A ˚) 0.009
RMSD bond angles (u) 1.660
Average B-factors (A ˚2) 18.046
Main chain (# atoms) 16.045 (312)
Side chain (# atoms) 18.394 (264)
Water (# atoms) 27.559 (56)
Ramachandran Plot
Most favored region (%) 93.4
Additional allowed regions (%) 4.9
Generously allowed regions (%) 1.6
Disallowed regions (%) 0.0
aNumbers in parentheses refer to the highest resolution shell.
bRsym = S|Ii – ,Ii.|/S| Ii|.
cRfactor = S||Fobs| 2 |Fcalc||/S|Fobs|.
dRfree equals the R factor against 5.9% of the data removed prior to refinement.
doi:10.1371/journal.pone.0015258.t001
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PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e15258Figure 1. Structure of CrSPI-1-D1. (A) Ribbon diagram of the CrSPI-1-D1. (B) 90u rotated side view. a-Helix, b-strands and random coils are
depicted in red, yellow and green, respectively. The disulfide bridges are shown in green. The secondary structures, N- and C-termini, are labeled. This
figure and the following figures of this manuscript were prepared using the program PyMOL [31].
doi:10.1371/journal.pone.0015258.g001
Figure 2. Comparison of CrSPI-1-D1 with rhodniin-D1. (A) Stereo Ca superposition of CrSPI-1-D1 (red) and rhodniin-D1 (cyan). The RMSD
between CrSPI-1-D1 and rhodniin-D1 is 2.0 A ˚ for 36 Ca atoms. (B) Structure based sequence alignment between CrSPI-1-D1 and rhodniin-D1. This
alignment was performed using the program COOT [28]. The secondary structural elements for CrSPI-1-D1 and rhodniin-D1 are shown at the top and
the bottom, respectively. The conserved residues are highlighted in red boxes outlined in blue. This figure was created by using the program ESPript
[32].
doi:10.1371/journal.pone.0015258.g002
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(Table 2). The closest similarities were observed with RSLs of
rhodniin-domain-1. P3, P2 and P1 of CrSPI-1-D1 and rhodniin-
D1 are similar, but P19,P 2 9,P 3 9 and P49 were different. Complex
crystal structure of rhodniin and thrombin showed that the N
terminal domain of rhodniin interacts with the active-site cleft
region of thrombin (PDB 1tbq). In addition to the interactions of
Pro9, His10 and Alall, the side chain of Leu12 occupies the S29
site of thrombin. His13 mediates a hydrogen bond and stacks with
aromatic residues in S39. Arg14 at P49 allows charge compensa-
tion of Glu39 from thrombin. The clustering of the positively
charged inhibitor residues at P39 and P49 might be particularly
beneficial for thrombin binding [23]. Based on rhodniin-D1:
thrombin complex structure a model for CrSPI-1-D1: thrombin
complex was constructed. This model showed that the RSL of
CrSPI-1-D1 fit well in the active site of thrombin (Figure 4). These
observations lead to the introduction of mutations in the RSL
region of CrSPI-1-D1 (Table S2), which was previously of
uncharacterized function, to specifically target thrombin.
Our approach was to mimic the P19,P 2 9,P 3 9 and P49 residues
(Thr4, Tyr5, Lys6 and Pro7) of CrSPI-1-D1 to rhodniin-D1
(Ala11, Leu12, His13 and Arg14); to sequentially mutate and
evaluate the implication of these four residues towards thrombin
inhibition. In addition to the tetra mutant, we have tried all
possible single, double and triple mutants. A total of 15 mutants
(Table 3) have been generated and their thrombin inhibition was
studied. All the mutants were expressed in bacteria and purified as
wild type CrSPI-1-D1 (Figure S1).The CD spectrum was recorded
on all 15 mutants of CrSPI-1-D1, which indicated that these
mutants share the same a/b structure as the wild type CrSPI-1-D1
(Figure S2). Furthermore, the ESI-MS spectrum showed their
expected molecular mass (Figure S3).
We have verified the stability of the CrSPI-1-D1 mutants as a
possible inhibitor against different serine proteases such as
thrombin, trypsin, chymotrypsin, elastase and subtilisin. Notably
only the tetra mutant is stable against thrombin, whereas other
serine proteases degrade the modified CrSPI-1-D1, which seemed
to act more as a substrate rather than an inhibitor (Figure S4). It
suggests that CrSPI-1-D1 mutant is thrombin-specific. In the
following section, we describe the inhibition studies of CrSPI-1-D1
mutants with thrombin.
Thrombin inhibition assay
Previously it has been shown that hirudin has very high
inhibitory activity against the human a-thrombin [24]. We chose
to study the properties of these CrSPI-1-D1 variants under a
similar condition as hirudin: human a- thrombin complex. Out of
all 15 CrSPI-1-D1 mutants, only tetra mutant (T4A, Y5K, K6H,
and P7R) showed the highest significant inhibition with human a-
thrombin in a dose-dependent manner.
Figure 5 shows the typical dose-response curves. Wild type
CrSPI-1-D1 showed no inhibition, whereas the tetra mutant
exhibited strong inhibition against thrombin. The dose response
plot of the fractional velocity as a function of different
concentrations of tetra mutant CrSPI-1-D1 showed that
26.3 nM of tetra mutant CrSPI-1-D1 was sufficient to inhibit
50% of 4.5 nM thrombin (Figure 6). Since the IC50 value of
26.3 nM is within a factor of 10 of the concentration of thrombin
and CrSPI-1-D1, it is ascertained that the mode of inhibition
follows the typical kazal domain’s mode of inhibition. Following
the inhibition studies, we verified the binding affinities of these
mutants of CrSPI-1-D1 with human a- thrombin using ITC
experiments.
Isothermal Titration Calorimetry (ITC) studies
To verify the interactions between the CrSPI-1-D1 and
thrombin, we have performed ITC experiments with wild type
Figure 3. The reactive-site loop (RSL). (A) The site-directed
mutation on CrSPI-1-D1. A transparent surface representation of the
CrSPI-1-D1 is shown with all mutated residues in stick representation in
magenta. (B) Stereo view of the electron density map. Simulated
annealing Fo-Fc omit map of the N-terminal region of CrSPI-1-D1
showing the key residues in reactive-site loop. All residues shown in this
figure as well as all atoms within 2 A ˚ of these residues were omitted
prior to refinement and map calculation. The map was contoured at a
level of 2.0 s. (C) A close view shows the interactions aid in maintaining
the rigidity of the RSL. Ca of the CrSPI-1-D1 is shown in red. The
disulfide bonds are shown in yellow, stick line while the hydrogen
bonds are shown in black, dotted lines.
doi:10.1371/journal.pone.0015258.g003
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CrSPI-1-D1 and the mutants which lacked thrombin inhibition
did not show any binding with thrombin. Consistent with the
results of thrombin inhibition assays, only the tetra mutant showed
interactions with human a- thrombin with dissociation constant
(Kd) of 4 mM (Figure 7). The model used for the ITC analysis is a
single site binding model assuming a stoichiometric ratio of 1:1
(CrSPI-1-D1: thrombin).
Discussion
The Carcinoscorpius rotundicauda is an ancient invertebrate that has
survived for several hundred million years, and thus termed a
‘living fossil’. Being able to efficiently defend against the multitude
of pathogens that thrive in its habitat and survive in this harsh
environment, suggests that it possesses a very powerful innate
Table 2. Reactive site loop regions from P3 to P49 position of selected serine protease inhibitors.
Inhibitors P3 P2 P1 P19 P29 P39 P49 Inhibitor against [ref.]
CrSPI-1 domain-1 Cys1 Pro2 His3 Thr4 Tyr5 Lys6 Pro7 Uncharac-
-terized
[10]
CrSPI-1 domain-2 Cys46 Thr47 Glu48 Glu49 Tyr50 Asp51 Pro52 Subtilisin [10]
rhodniin domain-1 Cys8 Pro9 His10 Ala11 Leu12 His13 Arg14 Thrombin [11]
rhodniin domain-2 Asp61 Gly62 Asp63 Glu64 Tyr65 Lys66 Pro67 Thrombin [11]
LDTI (Leech Derived Tryptase Inhibitor) Cys6 Pro7 Lys8 Ile9 Leu10 Lys11 Pro11 Trypsin [33]
Tomato inhibitor II domain-1 Cys3 Thr4 Arg5 Glu6 Cys7 Gly8 Asn9 Subtilisin [34]
Tomato inhibitor II dommain-2 Cys60 Thr61 Phe62 Asn63 Cys64 Asp65 Pro66 Subtilisin [34]
OMTKY3 Cys16 Thr17 Leu18 Glu19 Tyr20 Arg21 Pro22 Subtilisin [22]
Spn4A (Furin inhibitor
from Drosophila)
Arg371 Lys372 Arg373 Ala374 Ile375 Met376 Ser377 Furin [35]
Human PI8
(Furin Inhibitor)
Asn337 Ser338 Arg339 Cys340 Ser341 Arg342 Met343 Furin [36]
doi:10.1371/journal.pone.0015258.t002
Figure 4. Modeling complex of CrSPI-1-D1 with thrombin. (A)
Complex structure of rhodniin with thrombin (pdb code 1tbq). Rhodniin
and thrombin are shown in cyan and yellow, respectively. CrSPI-1-D1
(red) was superimposed on rhodniin-D1. (B) Thrombin is shown as
surface representation in this model complex. (C) Close up view of the
RSL of CrSPI-1-D1 in the active site of thrombin.
doi:10.1371/journal.pone.0015258.g004
Table 3. IC50 and dissociation constant (Kd) for the inhibition
of thrombin by various variants of CrSPI-1-D1.
S.No. Mutants IC50 Kd (dissociation Const.)
1 T4A ND ND
2 Y5K ND ND
3 K6H ND ND
4 P7R ND ND
5 T4A,Y5K ND ND
6 T4A,K6H ND ND
7 T4A,P7R ND ND
8 Y5K,K6H ND ND
9 Y5K,P7R ND ND
10 K6H,P7R ND ND
11 T4A,Y5K,K6H ND ND
12 T4A,Y5K,P7R ND ND
13 T4A,K6H,P7R ND ND
14 Y5K,K6H,P7R ND ND
15 T4A,Y5K,K6H,P7R 26.3 nM 4 mM
ND- not detected.
doi:10.1371/journal.pone.0015258.t003
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important roles in immunity by inactivating and clearing the
proteases from the invading pathogens, which use them as
virulence factors. How did multidomain SPIs arise? The SPI
domains are ‘evolutionarily mobile’ [25]. In the process of
evolution, domains from different families of SPIs could have
been shuffled and fused in a single inhibitor, resulting in a
multidomain inhibitor.
The evolutionary mechanisms of SPIs serve to increase their
variety and expand their functions, thus helping to meet the demands
of the repertoire of endogenous and exogenous SPs an organism
encounters. Thus, knowing the structure of an inhibitor usually
provides insights into its inhibitory functions. More importantly, the
structural changes of a protease inhibitor in complex with its target
protease can provide useful information on the interaction between
the two proteins, thus allowing the development of analogs of that
inhibitor with increased affinity towards the protease to achieve
greater inhibition capacity.Thismotivated us to modify the selectivity
of CrSPI-1-D1 to specifically target thrombin and here we show that
selected mutation in the RSL region of CrSPI-1-D1 led to a potent
and specific thrombin inhibitor.
We have determined the crystal structure of CrSPI-1-D1 refined
up to 2.0 A ˚ resolution, from the horseshoe crab, C. rotundicauda.
Although the native CrSPI-1-D1 itself is highly homologous to the
thrombin inhibitor, rhodniin domain 1 (rhodniin-D1), native
CrSPI-1-D1 does not inhibit thrombin. Therefore, our site directed
mutation of the RSL represents a structure-based drug design
approach in the conversion of an uncharacterized CrSPI-1-D1 into
a potent thrombin inhibitor with an IC50 of 26.3 nM. Furthermore,
our studies revealed that besides the rigid conformation of the RSL,
the sequence is most important in dictating the specificity of the
inhibitor. This study adds an important implication to modifying a
multidomain inhibitor protein. The CrSPI-1 has been shown to
target two molecules of proteases. The modified domain D1 targets
thrombin, whereas the wild type domain D2 targets subtilisin ([10];
Rajesh TS unpublished data). Moreover, this may lead to further
development of the D1 mutant into a shorter active anti-thrombin
inhibitor for therapeutic interventions.
Materials and Methods
Plasmid and strain construction
The CrSPI-1-D1 (encoding Cys1-Glu40) was PCR amplified
using forward CTACTGGATCCTGTCCTCAT and reverse
GCAGAGTTCGAATTCCTAGCAAGTTTCCCA primers that
Figure 5. Inhibition of human a-thrombin by increasing concentration of: (A) wild type CrSPI-1-D1 and (B) T4A, Y5K, K6H, P7R CrSPI-1-D1.
Residual protease activity was measured as OD405 based on hydrolysis of 0.1 mM S2238 (H-D-Phenylalanyl-L-pipecolyl-Larginine-p-nitroaniline
dihydrochloride) and formation of colored product, p-nitroaniline, by 4.5 nM thrombin in a total reaction volume of 200 mL. The concentration of wild
type CrSPI-1-D1 and T4A, Y5K, K6H, P7R CrSPI-1-D1 are indicated next to the curve.
doi:10.1371/journal.pone.0015258.g005
Figure 6. Determination of IC50 values based on dose response
plots of fractional velocity as a function of different tetra
mutant CrSPI-1-D1 concentration. OD405 was monitored based on
hydrolysis of 0.1 mM S2238 (H-D-Phenylalanyl-L-pipecolyl-Larginine-p-
nitroaniline dihydrochloride) and formation of colored product, p-
nitroaniline, by 4.5 nM thrombin in a total reaction volume of 200 mL. V0
and Vi are the initial velocities in the absence and presence of tetra
mutant CrSPI-1-D1, respectively and were calculated from Beer-
Lambert’s Law. The tetra mutant CrSPI-1-D1 concentration predicted
to block 50% of the activity of a fixed concentration of thrombin was
obtained on a graphical plot of Vi/V0 versus inhibitor concentration.
doi:10.1371/journal.pone.0015258.g006
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R1 site to the 39 end. Such PCR fragments were then digested
with Bam H1 and Eco R1, and ligated into pET-M vector, which
were previously linearized by compatible restriction enzymes, and
transformed into Escherichia coli, BL 21.
Purification
Optimal expression of the CrSPI-1-D1 in bacteria was obtained
by induction with 0.5 mM Isopropyl b-D-1-thiogalactopyranoside
(IPTG) of 1 liter culture at 25uC. The cells were then disrupted by
French Press and the supernatant were collected after centrifuging
at 10,000x g for 1 h at 4uC. His-tagged CrSPI-1-D1 proteins were
purified in two steps using Ni-NTA (Qiagen) affinity chromatog-
raphy followed by a Superdex 75 gel filtration column on the A ¨kta
Express (GE Healthcare). The buffer was exchanged to a solution
containing 20 mM Tris (pH-8.5), 150 mM NaCl, 5 mM dithio-
threitol (DTT) and finally concentrated up to 10 mg/ml.
Crystallization and structure determination
Initial crystallization conditions were screened at 25uC in the
hanging drop vapor diffusion technique using Hampton Research
crystallization screens and JB crystallization screens (Jena Biosci-
ences) with drops containing equal volumes (1 ml) of reservoir and
protein solution of 10 mg/ml against 0.5 ml of reservoir. Small
rod-shaped crystals were formed within 2–3 days. Further
optimization by equilibrating 1 ml CrSPI-1-D1 protein solution
of 15 mg/ml and 1 ml reservoir solution (0.4 M mono ammonium
dihydrogen sulphate, 0.1 M Tris-HCl pH 8.5) using hanging drop
vapor diffusion technique at 20uC led to best diffraction-quality
crystals. The crystals diffracted up to 2.0 A ˚ and belonged to space
group P21 with solvent content is approximately of 35% (Vm =
1.9 A ˚ 3/kDa).
Crystals were cryo-protected in the reservoir solution supple-
mented with 25–30% glycerol, and flash cooled at 100 K. The
diffraction data were obtained using a CCD detector (Platinum
135) mounted on a Bruker Microstar Ultra rotating anode
generator (Bruker AXS, Madison, WI). All datasets were processed
with HKL2000 [26]. The structures were solved by molecular
replacement with PHASER [27]. Subsequently the models were
manually built by using COOT [28], followed by refinement using
CNS [29]. The data collection and refinement statistics are
provided in Table 1.
Figure 7. Isothermal Titration Calorimetry analysis. (A) Human a- thrombin- wild type CrSPI-1-D1 titration. (B) Human a- thrombin - T4A, Y5K,
K6H, P7R CrSPI-1-D1 titration. The upper panels show the injection profile after baseline correction and the bottom panel shows the integration (heat
release) for each injection.
doi:10.1371/journal.pone.0015258.g007
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Based on the rhodniin-thrombin complex structure (PDB code
1tbq), residues Thr4, Tyr5, Lys6 and Pro7 of CrSPI-1-D1 were
mutated to Ala, Leu, His and Arg respectively. These are the
corresponding residues 8-11 of rhodniin that are crucial for interaction
with thrombin (Table S2). We used inverse PCR based mutagenesis
[30] to generate all mutants. In total, we generated 15 mutants (single
to tetra). All mutant inhibitor proteins were expressed in E. coli
(BL21DE3) using optimized expression conditions and purified by
His-tag based affinity and size exclusion column chromatography.
Further the purified CrSPI1-D1 was passed through the reverse phase
chromatography using an analytical Jupiter C18 column. The
molecular masses of the RP-HPLC purified mutants were determined
by ESI-MS on a Perkin-Elmer Sciex API III triple-stage quadrupole
instrument equipped with an ionspray interface.
CD spectroscopy
Far-UV CD spectra (260–190 nm) of CrSPI-1-D1 dissolved in
20 mM Tris-HCl buffer (pH 7.4) at a 30 mM protein concentra-
tion were collected using a Jasco J-810 spectropolarimeter (Easton,
MD). All measurements were carried out at room temperature
using 0.1-cm path length cuvettes with a scan speed of 50 nm/
min, a resolution of 0.2 nm, and a bandwidth of 2 nm.
Stability verification of CrSPI-1-D1 mutants against serine
proteases
20 mL of 1 mg/ml CrSPI-1-D1 mutants were incubated with 1 mL
of 1 mg/ml of different serine proteases such as thrombin, trypsin,
chymotrypsin, elastase and subtilisin at 37uC for 30 minutes. Reaction
was stopped by heating the sample with 5X SDS loading dye at
100uC. SDS PAGE was carried out following a standard protocol.
Inhibition of Thrombin Amidolytic Activity
The buffer used in all functional assays was 20 mM Tris-HCl,
pH 7.4. For all thrombin amidolytic activity assay, we used S2238
(H-D-Phenylalanyl-L-pipecolyl-Larginine-p-nitroaniline dihydro-
chloride), which is a chromogenic substrate for thrombin from
Chromogenix (Milano, Italy). To measure the inhibition activity of
different CrSPI-1-D1 proteins on thrombin activity, we performed all
reactionsin96-wellsmicrotiter plates.For each inhibition assay, 50 ml
of 4.5 nM human a- thrombin was pre-incubated for 30 minutes at
37uC with increasing amounts (10 to 70 nM) 50 ml of CrSPI-1-D1 in
a total reaction volume of 200 ml, prior to adding 100 ml of S2238.
The rate of formation of colored product, p-nitroaniline, was read
usinganenzyme-linkedimmunosorbentassayplatereaderat405 nm
for 10 minutes. Appropriate negative controls without the thrombin
was assayed simultaneously. Percentage inhibition was calculated by
taking the rate of increase in absorbance in the absence of inhibitor as
0%. A decrease in absorbance indicated the inhibitory effect of
CrSPI-1-D1 on thrombin activity.
Isothermal Titration Calorimetry (ITC)
The ITC experiments were carried out using VP-ITC calorim-
eter (Microcal, LLC) at 20uC using 300 mM of the protein in the
sample cell and 40 mM of human a-thrombin in the injector. All
samples were thoroughly degassed and then centrifuged to get rid of
precipitates. Volumes of 10 ml per injection were used for the
different experiments. For every experiment, the heat of dilution for
each ligand was measured and subtracted from the calorimetric
titration experimental 30 runs for the protein. Consecutive
injections were separated by at least 4 minutes to allow the peak
to return to the baseline. The ITC data was analyzed using a single
site fitting model using Origin 7.0 (OriginLab Corp.) software.
Accession Number
Coordinates of CrSPI-1-D1 have been deposited in the Protein
Data Bank (http://www.pdb.org) with accession code 3PIS.
Supporting Information
Table S1 Interactions associated for rigidity of reactive
site loop of CrSPI-1-D1.
(DOC)
Table S2 Site-directed mutagenesis strategy for CrSPI-
1-D1.
(DOC)
Figure S1 Reverse Phase-HPLC profile of CrSPI-1-D1.
The purified CrSPI-1-D1 was loadedonto an analytical JupiterC18
analytical column on SMART Workstation (GE-healthcare) and
eluted using a gradient (15 - 40% over 60 min) of buffer B (80%
ACN in 0.1% TFA. Figure shows the elution of protein monitored
at 215 nm. The peak (indicated with the arrow) contains a single
homogenous CrSPI-1-D1 taken for kinetics studies.
(TIF)
Figure S2 CD spectroscopy profile of reverse phase
HPLC purified CrSPI-1-D1. Far-UV CD spectra (260–
190 nm) of CrSPI-1-D1 dissolved in 20 mM Tris-HCl buffer
(pH 7.4) at a 30 mM protein concentration were collected using a
Jasco J-810 spectropolarimeter (Easton, MD). All measurements
were carried out at room temperature using 0.1-cm path length
cuvettes with a scan speed of 50 nm/min, a resolution of 0.2 nm,
and a bandwidth of 2 nm. The CD spectrum of the tetra mutant
of CrSPI-1-D1 indicated that it assumed an a/b structure.
(TIF)
Figure S3 ESI/MS profile of reversephase HPLC purified
CrSPI-1-D1. The spectrum shows a series of multiply charged ions,
corresponding to the correct molecular mass of 66446 0.22 Da. The
purity and mass of all mutant proteins of CrSPI-1-D1 were
determined by electro spray ionization mass spectrometry using an
API 300 liquid chromatography tandem mass spectrometry system
(PerkinElmer Life Sciences Sciex, Selton, CT).
(TIF)
Figure S4 The specificity of CrSPI-1-D1 tetra mutant for
thrombin ascertained by comparison with other prote-
ases. SDS-PAGE analysis for the interaction of CrSPI-1-D1 wild
type and tetra mutant with different proteases. A) Lane 1 protein
marker; Lane 2 CrSPI-1-D1 alone and Lane 3-7 CrSPI-1-D1 wild
type incubated with human a-thrombin, chymotrypsin, trypsin,
elastase and subtilisin, respectively, for 37uC for 30 minutes.
B) Lane 1 protein marker; Lane 2 T4A, Y5K, K6H, P7R CrSPI-
1-D1 alone and Lane 3-7 T4A,Y5K, K6H, P7R CrSPI-1-D1
incubated with human a-thrombin, chymotrypsin, trypsin, elastase
and subtilisin, respectively, for 37uC for 30 minutes.
(TIF)
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